alglucosidase alfa
Alimentary tract and metabolism (A16)US regulatory status: approved. Molecular target: Starch.
- Target
- Starch
- Mechanism
- Starch hydrolytic enzyme
pharma · Diphtheria · Diabetes Mellitus, Type 2
Sanofi Pasteur MSD
Sanofi Pasteur
Sanofi Pasteur MSD drug portfolio — 44 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
France, LYON HQ
363 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- France, LYON
- Employees
- 363
- Programs
- 2
- Drugs
- 44
- Patents
- 0
Sanofi Pasteur MSD pipeline
Portfolio lens on 44 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Sanofi Pasteur MSD drug portfolio — 44 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
alirocumab
Cardiovascular system (C10)US regulatory status: approved. Molecular target: Proprotein convertase subtilisin/kexin type 9.
- Target
- Proprotein convertase subtilisin/kexin type 9
- Mechanism
- Subtilisin/kexin type 9 inhibitor
-
Development asset linked to Sanofi Pasteur MSD in public FDA and regional records. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha degrader
-
cabazitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
cholera vaccine, oral, live
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sanofi Pasteur MSD's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sanofi Pasteur MSD's portfolio.
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Sanofi Pasteur MSD's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
dupilumab
Dermatologicals (D11)US regulatory status: approved. Molecular target: Interleukin-4 receptor subunit alpha.
- Target
- Interleukin-4 receptor subunit alpha
- Mechanism
- Interleukin-4 receptor subunit alpha antagonist
-
efmoroctocog alfa
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in Sanofi Pasteur MSD's portfolio. Molecular target: Coagulation factor VIII.
- Target
- Coagulation factor VIII
- Mechanism
- Coagulation factor VIII exogenous protein
-
Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.
-
enoxaparin sodium
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Antithrombin-III.
- Target
- Antithrombin-III
- Mechanism
- Antithrombin-III activator
-
Development asset linked to Sanofi Pasteur MSD in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
human heterologous liver cells
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Sanofi Pasteur MSD's portfolio.
-
Development asset linked to Sanofi Pasteur MSD in public FDA and regional records. Mechanism: Toll-like receptor 7 antagonist.
- Mechanism
- Toll-like receptor 7 antagonist
-
insulin glargine
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
insulin glulisine
Alimentary tract and metabolism (A10)Alimentary tract and metabolism (A10) compound in Sanofi Pasteur MSD's portfolio. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
insulin human
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
isatuximab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Sanofi Pasteur MSD's portfolio. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
- Target
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
- Mechanism
- Lymphocyte differentiation antigen CD38 inhibitor
-
japanese encephalitis vaccine (inactivated, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sanofi Pasteur MSD's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
leflunomide
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Dihydroorotate dehydrogenase (quinone), mitochondrial.
- Target
- Dihydroorotate dehydrogenase (quinone), mitochondrial
- Mechanism
- Dihydroorotate dehydrogenase inhibitor
-
lixisenatide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.
- Target
- Glucagon-like peptide 1 receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
meningococcal group a, c, w-135 and y conjugate vaccine
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sanofi Pasteur MSD's portfolio. Mechanism: Immunostimulant.
- Mechanism
- Immunostimulant
-
meningococcal groups a, c, w-135 and y conjugate vaccine
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Sanofi Pasteur MSD's portfolio. Mechanism: Immunostimulant.
- Mechanism
- Immunostimulant
-
octocog alfa
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in Sanofi Pasteur MSD's portfolio. Molecular target: Coagulation factor VIII.
- Target
- Coagulation factor VIII
- Mechanism
- Coagulation factor VIII exogenous protein
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Sanofi Pasteur MSD in public FDA and regional records. Mechanism: Norepinephrine transporter releasing agent.
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Angiotensin-converting enzyme.
- Target
- Angiotensin-converting enzyme
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
rimonabant
Alimentary tract and metabolism (A08)Alimentary tract and metabolism (A08) compound in Sanofi Pasteur MSD's portfolio. Molecular target: Cannabinoid receptor 1.
- Target
- Cannabinoid receptor 1
- Mechanism
- Cannabinoid CB1 receptor antagonist
-
Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Farnesyl pyrophosphate synthase.
- Target
- Farnesyl pyrophosphate synthase
- Mechanism
- Farnesyl diphosphate synthase inhibitor
-
Development asset linked to Sanofi Pasteur MSD in public FDA and regional records.
-
sarilumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.
- Target
- Interleukin-6 receptor subunit alpha
- Mechanism
- Interleukin-6 receptor alpha subunit antagonist
-
Development asset linked to Sanofi Pasteur MSD in public FDA and regional records. Molecular target: Antithrombin-III.
- Target
- Antithrombin-III
- Mechanism
- Antithrombin-III inhibitor
-
sevelamer
Various (V03)Various (V03) compound in Sanofi Pasteur MSD's portfolio.
-
US regulatory status: approved.
-
teplizumab
Alimentary tract and metabolism (A10)Alimentary tract and metabolism (A10) compound in Sanofi Pasteur MSD's portfolio. Molecular target: T-cell surface glycoprotein CD3 epsilon chain.
- Target
- T-cell surface glycoprotein CD3 epsilon chain
- Mechanism
- T-cell surface glycoprotein CD3 epsilon chain other
-
Development asset linked to Sanofi Pasteur MSD in public FDA and regional records. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
vandetanib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Ephrin receptor.
- Target
- Ephrin receptor
- Mechanism
- Ephrin receptor inhibitor